SKAN Group AG informs about the ongoing investigation of the Office of the Attorney General of Switzerland

SKAN AG / Key word(s): Miscellaneous

26-May-2023 / 17:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR
 

SKAN Group AG informs about the ongoing investigation of the Office of the Attorney General of Switzerland

Allschwil, 26 May 2023 – Dr. Gert Thoenen, Chairman of the Board of Directors of SKAN Group AG, respectively a person close to him is involved in a transaction which is subject of the ongoing investigation by the Office of the Attorney General of Switzerland due to possible insider trading. For this reason, he is abstaining for the duration of the ongoing investigation. Cornelia Gehrig, Vice Chairman of the Board of Directors, has taken over the management of the business of the Board of Directors.

The investigation by the Office of the Attorney General of Switzerland relates to transactions with shares of BV Holding AG from the period before the IPO. In addition to the Chairman of the Board of Directors, two employees of SKAN are involved in the ongoing investigation. SKAN Group AG states that no former executive bodies of the previous BV Holding AG and none of the current anchor shareholders of SKAN Group AG are involved in the ongoing investigation. Of course, the presumption of innocence applies to all those involved.

SKAN Group AG has the greatest interest in the ongoing investigation being concluded as quickly as possible and is cooperating closely with the investigating authorities. As soon as further findings result from the investigation, SKAN Group AG will inform again.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organization make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organizations) and research laboratories worldwide. Founded in 1968, SKAN today employs over 1170 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan and the USA.